These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 10737881)

  • 1. Characterization of a polymeric PLGA-injectable implant delivery system for the controlled release of proteins.
    Eliaz RE; Kost J
    J Biomed Mater Res; 2000 Jun; 50(3):388-96. PubMed ID: 10737881
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Formulation and characterization of injectable poly(DL-lactide-co-glycolide) implants loaded with N-acetylcysteine, a MMP inhibitor.
    Desai KG; Mallery SR; Schwendeman SP
    Pharm Res; 2008 Mar; 25(3):586-97. PubMed ID: 17891553
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Encapsulation and stabilization of nerve growth factor into poly(lactic-co-glycolic) acid microspheres.
    Lam XM; Duenas ET; Cleland JL
    J Pharm Sci; 2001 Sep; 90(9):1356-65. PubMed ID: 11745788
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibiotic-loaded plaster of Paris implants coated with poly lactide-co-glycolide as a controlled release delivery system for the treatment of bone infections.
    Benoit MA; Mousset B; Delloye C; Bouillet R; Gillard J
    Int Orthop; 1997; 21(6):403-8. PubMed ID: 9498152
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent advances in the stabilization of proteins encapsulated in injectable PLGA delivery systems.
    Schwendeman SP
    Crit Rev Ther Drug Carrier Syst; 2002; 19(1):73-98. PubMed ID: 12046892
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro and in vivo evaluation in rabbits of a controlled release 5-fluorouracil subconjunctival implant based on poly(D,L-lactide-co-glycolide).
    Wang G; Tucker IG; Roberts MS; Hirst LW
    Pharm Res; 1996 Jul; 13(7):1059-64. PubMed ID: 8842045
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Release behavior of poly(lactic acid-co-glycolic acid) implants containing phosphorothioate oligodeoxynucleotide.
    Yamakawa I; Ishida M; Kato T; Ando H; Asakawa N
    Biol Pharm Bull; 1997 Apr; 20(4):455-9. PubMed ID: 9145231
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fabrication and characterization of controlled release poly(D,L-lactide-co-glycolide) millirods.
    Qian F; Szymanski A; Gao J
    J Biomed Mater Res; 2001 Jun; 55(4):512-22. PubMed ID: 11288079
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chitin/PLGA blend microspheres as a biodegradable drug delivery system: a new delivery system for protein.
    Mi FL; Shyu SS; Lin YM; Wu YB; Peng CK; Tsai YH
    Biomaterials; 2003 Dec; 24(27):5023-36. PubMed ID: 14559016
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dexamethasone/PLGA microspheres for continuous delivery of an anti-inflammatory drug for implantable medical devices.
    Hickey T; Kreutzer D; Burgess DJ; Moussy F
    Biomaterials; 2002 Apr; 23(7):1649-56. PubMed ID: 11922468
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preparation and characterization of cationic PLGA nanospheres as DNA carriers.
    Ravi Kumar MN; Bakowsky U; Lehr CM
    Biomaterials; 2004 May; 25(10):1771-7. PubMed ID: 14738840
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of the poly(lactide-co-glycolide) type on the leuprolide release from in situ forming microparticle systems.
    Luan X; Bodmeier R
    J Control Release; 2006 Jan; 110(2):266-272. PubMed ID: 16300851
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Injectable in situ forming depot systems: PEG-DAE as novel solvent for improved PLGA storage stability.
    Schoenhammer K; Petersen H; Guethlein F; Goepferich A
    Int J Pharm; 2009 Apr; 371(1-2):33-9. PubMed ID: 19135512
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Controlled delivery of the anti-VEGF aptamer EYE001 with poly(lactic-co-glycolic)acid microspheres.
    Carrasquillo KG; Ricker JA; Rigas IK; Miller JW; Gragoudas ES; Adamis AP
    Invest Ophthalmol Vis Sci; 2003 Jan; 44(1):290-9. PubMed ID: 12506087
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The manufacturing techniques of various drug loaded biodegradable poly(lactide-co-glycolide) (PLGA) devices.
    Jain RA
    Biomaterials; 2000 Dec; 21(23):2475-90. PubMed ID: 11055295
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polylactide-polyglycolide delivery system for physostigmine.
    Hussain MA; Mollica JA
    J Pharm Sci; 1993 May; 82(5):553-4. PubMed ID: 8360838
    [No Abstract]   [Full Text] [Related]  

  • 17. Instability of bovine insulin in poly(lactide-co-glycolide) (PLGA) microspheres.
    Uchida T; Yagi A; Oda Y; Nakada Y; Goto S
    Chem Pharm Bull (Tokyo); 1996 Jan; 44(1):235-6. PubMed ID: 8582042
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the effects of Mg(OH)2 and sucrose on the stability of bovine serum albumin encapsulated in injectable poly(D,L-lactide-co-glycolide) implants.
    Kang J; Schwendeman SP
    Biomaterials; 2002 Jan; 23(1):239-45. PubMed ID: 11762843
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dexamethasone-releasing biodegradable polymer scaffolds fabricated by a gas-foaming/salt-leaching method.
    Yoon JJ; Kim JH; Park TG
    Biomaterials; 2003 Jun; 24(13):2323-9. PubMed ID: 12699670
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chitin/PLGA blend microspheres as a biodegradable drug-delivery system: phase-separation, degradation and release behavior.
    Mi FL; Lin YM; Wu YB; Shyu SS; Tsai YH
    Biomaterials; 2002 Aug; 23(15):3257-67. PubMed ID: 12102197
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.